Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Viruses. 2022 Jun 5;14(6):1226. doi: 10.3390/v14061226.
Mosquito-borne flavivirus infections affect approximately 400 million people worldwide each year and are global threats to public health. The common diseases caused by such flaviviruses include West Nile, yellow fever, dengue, Zika infection and Japanese encephalitis, which may result in severe symptoms and disorders of multiple organs or even fatal outcomes. Till now, no specific antiviral agents are commercially available for the treatment of the diseases. Numerous strategies have been adopted to develop novel and promising inhibitors against mosquito-borne flaviviruses, including drugs targeting the critical viral components or essential host factors during infection. Research advances in antiflaviviral therapy might optimize and widen the treatment options for flavivirus infection. This review summarizes the current developmental progresses and involved molecular mechanisms of antiviral agents against mosquito-borne flaviviruses.
蚊媒黄病毒感染每年影响全球约 4 亿人，是全球公共卫生的威胁。此类黄病毒引起的常见疾病包括西尼罗河病毒、黄热病、登革热、寨卡病毒感染和日本脑炎，可能导致严重症状和多器官紊乱，甚至致命后果。到目前为止，还没有针对这些疾病的商业上可用的特定抗病毒药物。人们已经采取了许多策略来开发针对蚊媒黄病毒的新型有前途的抑制剂，包括针对感染过程中关键病毒成分或必要宿主因子的药物。抗黄病毒治疗的研究进展可能会优化和拓宽黄病毒感染的治疗选择。本综述总结了针对蚊媒黄病毒的抗病毒药物的当前发展进展和涉及的分子机制。
